Active	Status	Sponsor type	Region	Phase	Filter
3 Active 6 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
seviteronel (INO-464) / Innocrin
ACTRN12618001074280: Intervention study assessing the novel use of seviteronel in androgen receptor positive cancers	Recruiting	2	16			St Vincent's Hospital, Innocrin Pharmaceuticals Inc	Solid cancers
2011-004103-20: A study of the safety, pharmacokinetics and effects of seviteronel in men with prostate cancer that does not respond to hormone treatment	Ongoing	1/2	154	Europe	INO-464, INO-464, Tablet	Innocrin Pharmaceuticals, Inc., Viamet Pharmaceuticals, Inc., Innocrin Pharmaceuticals, Inc., Viamet Pharmaceuticals, Inc.	Castration-resistant prostate cancer (CRPC), Cancer of the prostate gland that has become hormone resistant, Diseases [C] - Cancer [C04]
4CAST, NCT04947189: Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	Recruiting	1/2	65	RoW	Seviteronel-D (Seivteronel in combination with dexamethasone), INO-464, Docetaxel	St Vincent's Hospital, Sydney	Triple Negative Breast Cancer	07/26	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
seviteronel (INO-464) / Innocrin
ACTRN12618001074280: Intervention study assessing the novel use of seviteronel in androgen receptor positive cancers	Recruiting	2	16			St Vincent's Hospital, Innocrin Pharmaceuticals Inc	Solid cancers
2011-004103-20: A study of the safety, pharmacokinetics and effects of seviteronel in men with prostate cancer that does not respond to hormone treatment	Ongoing	1/2	154	Europe	INO-464, INO-464, Tablet	Innocrin Pharmaceuticals, Inc., Viamet Pharmaceuticals, Inc., Innocrin Pharmaceuticals, Inc., Viamet Pharmaceuticals, Inc.	Castration-resistant prostate cancer (CRPC), Cancer of the prostate gland that has become hormone resistant, Diseases [C] - Cancer [C04]
4CAST, NCT04947189: Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	Recruiting	1/2	65	RoW	Seviteronel-D (Seivteronel in combination with dexamethasone), INO-464, Docetaxel	St Vincent's Hospital, Sydney	Triple Negative Breast Cancer	07/26	12/27